Orthofix Medical (NASDAQ:OFIX) is set to post its quarterly earnings results after the market closes on Monday, October 29th. Analysts expect Orthofix Medical to post earnings of $0.37 per share for the quarter. Orthofix Medical has set its Q3 guidance at $0.35-0.79 EPS and its FY18 guidance at $1.66-1.72 EPS.
Orthofix Medical (NASDAQ:OFIX) last announced its quarterly earnings results on Monday, August 6th. The medical device company reported $0.42 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.36 by $0.06. The company had revenue of $111.50 million for the quarter, compared to analyst estimates of $114.62 million. Orthofix Medical had a net margin of 2.53% and a return on equity of 10.74%. Orthofix Medical’s revenue for the quarter was up 2.4% on a year-over-year basis. During the same quarter last year, the business earned $0.42 EPS. On average, analysts expect Orthofix Medical to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.
Shares of OFIX opened at $56.47 on Friday. The firm has a market capitalization of $1.08 billion, a price-to-earnings ratio of 34.86, a P/E/G ratio of 3.54 and a beta of 0.36. Orthofix Medical has a fifty-two week low of $48.30 and a fifty-two week high of $61.98.
A number of equities analysts have weighed in on the stock. BidaskClub lowered shares of Orthofix Medical from a “strong-buy” rating to a “buy” rating in a report on Tuesday, July 17th. Zacks Investment Research raised shares of Orthofix Medical from a “strong sell” rating to a “hold” rating in a research note on Wednesday, July 4th. Cantor Fitzgerald raised their target price on shares of Orthofix Medical to $66.00 and gave the company an “overweight” rating in a research note on Tuesday, August 7th. Finally, TheStreet raised shares of Orthofix Medical from a “c+” rating to a “b-” rating in a research note on Monday, September 10th. One analyst has rated the stock with a sell rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $62.25.
Orthofix Medical Company Profile
Orthofix Medical Inc, a medical device company, provides musculoskeletal healing products and value-added services worldwide. It operates through four segments: BioStim, Extremity Fixation, Spine Fixation, and Biologics. The BioStim segment manufactures, distributes, and provides support services for bone growth stimulator devices that enhance bone fusion and are indicated as treatment to enhance fusion success rates in cervical and lumbar spine, as well as a therapeutic treatment for non-spine fractures.
Read More: Why Dividend Stocks May Be Right for You
Receive News & Ratings for Orthofix Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthofix Medical and related companies with MarketBeat.com's FREE daily email newsletter.